Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Antihypertensive Effect of Different Doses of ROSTAFUROXIN in Comparison With Losartan, Assessed by Office and Ambulatory Blood Pressure Monitoring in a Hypertensive Population Selected According to a Specific Genetic Profile.

Next Previous
Trial Profile

Antihypertensive Effect of Different Doses of ROSTAFUROXIN in Comparison With Losartan, Assessed by Office and Ambulatory Blood Pressure Monitoring in a Hypertensive Population Selected According to a Specific Genetic Profile.

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 30 Apr 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rostafuroxin (Primary) ; Losartan
  • Indications Hypertension
  • Focus Pharmacogenomic; Therapeutic Use
  • Sponsors CVie Therapeutics; Windtree Therapeutics

    • Most Recent Events

    • 22 Dec 2015 According to a Lee's Pharmaceutical Holdings media release, enrollment has been completed in Italy in November 2015 and the first patient from Taiwan has been enrolled on 18 December 2015. The company expects to complete enrollment in Taiwan in June 2016.
    • 12 Jun 2013 Status changed from planning to recruiting, according to a Lee's Pharmaceutical Holdings media release. The first patient has been enrolled.
    • 13 Aug 2012 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top